Chong Kun Dang Q1 2026: Wegovy Sales Surge & R&D Investment Growth

Consolidated revenue of KRW 447.8 billion, operating profit of KRW 14.1 billion
Wegovy (obesity drug) Q1 sales of KRW 48.8 billion, surged from KRW 9.2 billion in full 2025
R&D spending of KRW 50.0 billion, 11.2% of revenue
CKD-510 (atrial fibrillation) licensed to Novartis, global Phase 2 ongoing
Credit rating maintained at AA-, stable financial structure
No additional share buyback or cancellation; exchangeable bonds issued on treasury shares
Ongoing appeal in choline alfoscerate clinical re-evaluation litigation